MARIETTA, Ga., Aug. 9, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received regulatory approval from the Therapeutics Goods Administration (TGA) in Australia to market and sell a broad array of the Company’s dehydrated Human Amnion/Chorion Membrane (dHACM) products. This includes EpiFix®, AmnioFix®, EpiBurn®, AmnioFix Injectable, and […]